Tag Archives: act

Actavis Nabs Allergan For $66 Billion; Valeant Folds

One of the most widely rumored deals in pharma came to fruition Monday, as Actavis (ACT) agreed to acquire Allergan (AGN) for $66 billion in cash and stock. Allergan stock was up more than 7%, near 213, and Actavis stock up nearly 4%, near 253, in early trading in the stock market today. Actavis agreed to pay $129.22 in cash along with 0.3683 Actavis share for each share of Allergan, which based on Actavis’ Friday closing price values Allergan at

Actavis, Allergan Reported Near Deal As Valeant Lurks

The drug-industry rumor mill got a fresh surge of energy Wednesday on a report that emerging drug giant Actavis (ACT) is nearing a deal to buy Botox maker Allergan (AGN) for at least $60 billion. Reports that the two companies were talking have been leaking out for a couple months now, and the subject was a major, if unnamed, topic of Actavis’ Q3 earnings call last week. However, Bloomberg’s latest report has anonymous sources saying an agreement

Actavis Beats Q3 Estimates As Buyout Talk Swirls

Generic and specialty drug giant Actavis (ACT) beat Wall Street’s Q3 estimates and raised its guidance early Wednesday, sending shares up more than 3% in early trading in the stock market today to a new high above 254. By midmorning, though, the stock was up just a fraction, near 246. Actavis’ earnings, excluding one-time items, rose 53% over the year-earlier quarter to $3.19 a share, beating analysts’ consensus by 9 cents, according to Thomson